Large-scale testing (Phase 3)Study completedNCT01362140What this trial is testingDarbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Who this might be right forMDS Amgen 147
Testing effectiveness (Phase 2)UnknownNCT00513578What this trial is testingVaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndromes The Vaccine Company 30
Post-approval studies (Phase 4)Study completedNCT02145026What this trial is testingEpoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)Who this might be right forMyelodysplastic Syndromes Hoffmann-La Roche 100
Testing effectiveness (Phase 2)Study completedNCT02269280What this trial is testingPhase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)Who this might be right forLeukemia M.D. Anderson Cancer Center 185
Large-scale testing (Phase 3)Study completedNCT02175277What this trial is testingDarbepoetin Alfa MDS Companion ProtocolWho this might be right forMyelodysplastic Syndrome (MDS) Amgen 9
Large-scale testing (Phase 3)Ended earlyNCT02158936What this trial is testingEltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)Who this might be right forThrombocytopaenia Novartis Pharmaceuticals 356
Testing effectiveness (Phase 2)Study completedNCT01720225What this trial is testingDecitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskWho this might be right forLeukemia M.D. Anderson Cancer Center 113
Testing effectiveness (Phase 2)Ended earlyNCT01542684What this trial is testingStudy of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)Who this might be right forLeukemia M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Study completedNCT01718379What this trial is testingLenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.Who this might be right forMyelodysplastic Syndromes Groupe Francophone des Myelodysplasies 132
Not applicableStudy completedNCT02757989What this trial is testingAllogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low RiskWho this might be right forMDS Groupe Francophone des Myelodysplasies 79
Testing effectiveness (Phase 2)Ended earlyNCT01459159What this trial is testingStudy of (Telintra®) in Non-Del(5q) Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome (MDS) Telik 162
Testing effectiveness (Phase 2)Study completedNCT01133275What this trial is testingLenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDSWho this might be right forMyelodysplastic SyndromeMDS H. Lee Moffitt Cancer Center and Research Institute 28
Testing effectiveness (Phase 2)Study completedNCT01081431What this trial is testingSafety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5qWho this might be right forMyelodysplastic Syndromes Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 91
Testing effectiveness (Phase 2)Study completedNCT00614523What this trial is testingRomiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Who this might be right forMDSMyelodysplastic SyndromesThrombocytopenia Amgen 250
Testing effectiveness (Phase 2)Study completedNCT01749514What this trial is testingStudy of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)Who this might be right forAnemia Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 116
Testing effectiveness (Phase 2)UnknownNCT04988815What this trial is testingRopeginterferon Alfa 2b for Early MyelofibrosisWho this might be right forPrimary Myelofibrosis, Prefibrotic StageMyelofibrosis The University of Hong Kong 50
Testing effectiveness (Phase 2)Study completedNCT02159872What this trial is testingOmacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) FailureWho this might be right forLeukemia M.D. Anderson Cancer Center 48
Testing effectiveness (Phase 2)Ended earlyNCT00542828What this trial is testingRabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome (MDS) Genzyme, a Sanofi Company 16
Testing effectiveness (Phase 2)Study completedNCT01015352What this trial is testingAzacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)Who this might be right forMyelodysplastic Syndromes Groupe Francophone des Myelodysplasies 98
Testing effectiveness (Phase 2)Looking for participantsNCT03886662What this trial is testingLB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)Who this might be right forMyelodysplastic Syndromes Lixte Biotechnology Holdings, Inc. 47